Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Leukemia, Myeloid, Acute 3Metastatic Pancreatic Adenocarcinoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Adenocarcinoma 1

Interventions

Gemcitabine 3pembrolizumab 2Leucovorin 2Fluorouracil 24-fluorobenzoyl-TN-14003 2regorafenib 1olaparib 1irinotecan sucrosofate 1Taxes 1Oxaliplatin 1Irinotecan 1Erlotinib Hydrochloride 1Drug Therapy 1BKT140 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Pancreatic Adenocarcinoma × 4-fluorobenzoyl-TN-14003 × Clear all
NCT02907099 2025-02-19

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
20 enrolled 12 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02826486 2024-08-28

COMBAT

BioLineRx, Ltd.

Phase 2 Completed
80 enrolled 13 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡